ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Oragenics Inc

Oragenics Inc (OGEN)

0.27471
-0.01329
( -4.61% )
Updated: 10:24:13

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.27471
Bid
-
Ask
-
Volume
85,707
0.265 Day's Range 0.2964
0.2542 52 Week Range 7.74
Market Cap
Previous Close
0.288
Open
0.28
Last Trade
46
@
0.270101
Last Trade Time
10:24:42
Financial Volume
$ 23,795
VWAP
0.277629
Average Volume (3m)
539,675
Shares Outstanding
12,212,680
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
38k
Net Profit
-20.66M

About Oragenics Inc

Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other ho... Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Tampa, Florida, USA
Founded
-
Oragenics Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker OGEN. The last closing price for Oragenics was $0.29. Over the last year, Oragenics shares have traded in a share price range of $ 0.2542 to $ 7.74.

Oragenics currently has 12,212,680 shares outstanding. The market capitalization of Oragenics is $3.52 million.

OGEN Latest News

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.06529-19.20294117650.340.350.254211589610.31195893CS
4-0.06939-20.16564952050.34410.430.25426379660.33777557CS
12-0.75529-73.32912621361.031.290.25425396750.41135954CS
26-2.82529-91.13838709683.13.20.25425417550.97744848CS
52-3.27529-92.26169014083.557.740.25423168231.12428732CS
156-33.92529-99.19675438634.237.505940.254244774317.32567275CS
260-29.24529-99.069410569129.52127.20.2542304024449.29884131CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BIGYYieldmax Target 12 Big 50 Option Income ETF
 49.815
(175.37%)
7.6k
SNOYYieldmax Snow Option Income Strategy ETF
$ 21.79
(24.09%)
23.99k
ETUT Rex 2X Long Ether Daily Target ETF
$ 41.38
(17.16%)
27.24k
ETHU2x Ether ETF
$ 8.55
(15.70%)
20.46M
ETHTProshares Ultra Ether ETF
$ 23.67
(15.63%)
436.44k
CATXPerspective Therapeutics Inc
$ 3.32
(-46.19%)
2.9M
CHROChannel Therapeutics Corporation
$ 0.5099
(-17.65%)
38.96k
ETHDProshares Ultrashort Ether ETF
$ 26.27
(-16.44%)
60.76k
ETQT Rex 2X Inverse Ether Daily Target ETF
$ 11.91
(-15.62%)
2.77k
ROLRHigh Roller Technologies Inc
$ 6.15
(-15.17%)
9.94k
MSTZT Rex 2X Inverse MSTR Daily Target ETF
$ 0.7747
(-4.69%)
438.45M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 27.39
(0.96%)
36.26M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
$ 3.14
(2.61%)
25.54M
ETHU2x Ether ETF
$ 8.55
(15.70%)
20.83M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 24.395
(-0.95%)
15.3M

OGEN Discussion

View Posts
Monksdream Monksdream 2 weeks ago
OGEN 10Q due 11/11
πŸ‘οΈ0
willlbone willlbone 3 months ago
Dilution at 55 cents. Sell.
πŸ‘οΈ0
williams45 williams45 3 months ago
Oragenics Inc. ($OGEN) is a healthcare innovator focusing on novel antibiotics and treatments for oral mucositis. With a 52-week range of $0.86 to $7.74, it is advancing products like OG716, LBPs, and Terra CoV-2 immunization.
πŸ‘οΈ0
retired early retired early 3 months ago
WOW more weak hands. And with only 5.6 mil os :)
πŸ‘οΈ0
retired early retired early 3 months ago
The average one-year price target for Oragenics, Inc. is $91.80. :)
πŸ‘οΈ0
retired early retired early 3 months ago
Weak many hands are gone, new investors welcome. :)
πŸ‘οΈ0
retired early retired early 3 months ago
Weak many hands are gone, new investors welcome. :)
πŸ‘οΈ0
retired early retired early 3 months ago
Not for long. :)
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
OGEN under $2
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
OGEN under $2
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
OGEN 10Q due 3/19
πŸ‘οΈ0
willlbone willlbone 10 months ago
China Dump
πŸ‘οΈ0
JDCruz JDCruz 1 year ago
News just hit! Oragenics Issues Update to Shareholders:
https://www.otcmarkets.com/stock/OGEN/news/story?e&id=2676834
πŸ‘οΈ0
JDCruz JDCruz 1 year ago
OGEN steady rise looks like this biotech is ready to run!
πŸ‘οΈ0
retired early retired early 1 year ago
Will this turd float to the surface? :)
πŸ‘οΈ0
retired early retired early 2 years ago
Maybe not. :)
πŸ‘οΈ0
Nathan123456 Nathan123456 2 years ago
Don't madder they will short it down to nothing
πŸ‘οΈ0
retired early retired early 2 years ago
Surfs up. ::)
πŸ‘οΈ0
BEIJING BILL BEIJING BILL 2 years ago
Chart setup perfectly here -> time is koming for the super spike

https://stockcharts.com/h-sc/ui?s=ogen
πŸ‘οΈ0
retired early retired early 2 years ago
Hey whatever it takes to see it rise to the moon but wow hats off to your sacrifice. :)
πŸ‘οΈ0
THEMASTERS_SON THEMASTERS_SON 3 years ago
,,,,,,,I’m out
πŸ‘οΈ0
unpathedhaunt unpathedhaunt 3 years ago
3/22 Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

"β€œWe are thrilled to have begun this pivotal study with Frontage, a premier drug development contract research organization, and are thankful to the acceleration Frontage has offered our important IND-enabling study. We believe the results from this rabbit toxicology study will support our development strategy for our intranasal COVID-19 vaccine candidate, NT-CoV2-1. The intranasal delivery route is particularly relevant as it may further reduce transmission of the virus and provide a needle-free delivery option. The findings from this preclinical toxicology study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration,” said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics."


https://ir.oragenics.com/press-releases/detail/142

πŸ‘οΈ0
BEIJING BILL BEIJING BILL 3 years ago
KABOOM !! ve got movement!!
πŸ‘οΈ0
retired early retired early 3 years ago
Looks like word is getting out. :)
πŸ‘οΈ0
retired early retired early 3 years ago
I agree. The buy consensus is at 83%.3 days ago. I think info is near. :)
πŸ‘οΈ0
Nathans123 Nathans123 3 years ago
HUGE insider buy
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
OGEN HOD
πŸ‘οΈ0
shurtha2000 shurtha2000 3 years ago
lets get this back over $1
πŸ‘οΈ0
alisher alisher 3 years ago
Oragenics (OGEN) Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

Agreement extends current licensing and collaboration agreement to include rapid production of Omicron-specific intranasal vaccine candidates

TAMPA, Fla., December 20, 2021--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant. The NRC cell expression technologies provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines. The NRC technologies, developed with support from the NRC’s Pandemic Response Challenge program, will expedite the evaluation of an Omicron-specific Terra-CoV-2 candidate in preclinical and clinical studies.

"Oragenics is well-positioned to develop an Omicron-specific intranasal vaccine thanks to our successful, on-going collaboration with the NRC," said Frederick W. Telling, Ph.D., Oragenics’ Executive Chairman. "We had anticipated the need for rapid development of COVID-19 vaccine candidates against new variants and can leverage the NRC cell expression platform to address Omicron and future variants."

Oragenics recently demonstrated the protection of hamsters against SARS-CoV-2 with the intranasal Terra-CoV-2 candidate, which strongly supports the further development into an IND-enabling GLP toxicology study and a first-in-human Phase 1 clinical study.

https://finance.yahoo.com/news/oragenics-extends-collaboration-national-research-130000929.html
πŸ‘οΈ0
alisher alisher 3 years ago
Oragenics Announces Positive COVID-19 Challenge Study Results

Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.

Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. The vaccines delivered by intranasal and intramuscular routes generated immune responses as measured by multiple assays.

"The very positive results from this hamster challenge study fully support our further development of either the intranasal or intramuscular routes of administration, however we plan to focus on the intranasal delivery route for the Terra CoV-2 vaccine due to the relative lack of competition and anticipated advantages of intranasal vaccine delivery, such as reducing viral transmission, needle-free administration, and ease of distribution, as well as the potential for conferred mucosal immunity which is presently being studied. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the second quarter of 2022, and should facilitate advancement of the program into human clinical studies," said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.

https://finance.yahoo.com/news/oragenics-announces-positive-covid-19-130000711.html
πŸ‘οΈ0
Renegade Rich Renegade Rich 3 years ago
News!
πŸ‘οΈ0
Mountainman5 Mountainman5 3 years ago
ORAGENICS is really on a good way to achieve soon $ 10 or more!!!!!!!!!!!!!!!!!!!!!!!!!!
πŸ‘οΈ0
retired early retired early 3 years ago
Opps good call. I own both and posted on the wrong board. :)
πŸ‘οΈ0
oakrock oakrock 3 years ago
How does that help OGEN?
πŸ‘οΈ0
retired early retired early 3 years ago
Qiagen has received emergency use authorization from the U.S. Food and Drug Administration for its QIAreach SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results. :)
πŸ‘οΈ0
oakrock oakrock 3 years ago
OGEN will be a player....opportunity knocks.
πŸ‘οΈ0
GREGG THE GREEK GREGG THE GREEK 3 years ago
Been a nice atm.


OGEN
πŸ‘οΈ0
Lowhndcpr Lowhndcpr 3 years ago
What will happen today? Morning dip into low 70s to add?
Every time this stock runs….she sells off Next couple days. We shall see
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Here comes eod volume
πŸ‘οΈ0
shurtha2000 shurtha2000 3 years ago
$100-$200M from Canadian govt funding ?
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Should thin out soon
πŸ‘οΈ0
retired early retired early 3 years ago
EPIC :)
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Could be epic
πŸ‘οΈ0
bigbut bigbut 3 years ago
Big day looming here after OGEN announcement of work with Canadian Government on fast track vaccine alternatives.
πŸ‘οΈ0
Lowhndcpr Lowhndcpr 3 years ago
Nice day here. Need to get back to a buck soon
πŸ‘οΈ0
420man 420man 3 years ago
O-0
πŸ‘οΈ0
dancy dancy 4 years ago
OGEN cover time
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $OGEN Video Chart 04-23-2021 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
retired early retired early 4 years ago
It's all about the therapeutics, peutics, peutics. :)
πŸ‘οΈ0
trendzone trendzone 4 years ago
It's time for the CEO to get his head out of his toxic azz.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock